ReviewCell communication and signaling : CCS2026
Bacterial extracellular vesicles in colorectal cancer: mechanisms, biomarker potential, and therapeutic engineering.
Review in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bacterial and gut microbiota-derived extracellular vesicles as emerging sources of cancer biomarkers: molecular mechanisms, diagnostic approaches, and therapeutic applications.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) is a leading cause of cancer-related deaths. The human colon, which hosts a vast and complex microbial ecosystem, plays a crucial role in health and disease, with approximately 20% of human cancers linked to microbial dysbiosis. Bacterial extracellular vesicles (BEVs) serve as critical mediators of host-microbe communication, influencing both physiological and pathological processes.
methodsIn this narrative review study, we surveyed the literature published on the multifaceted roles of BEVs, derived from various bacterial strains, in the pathogenesis and treatment of CRC, using databases such as Google Scholar, Scopus, ScienceDirect, PubMed, and Web of Science.
resultsBEVs carry a diverse cargo, including proteins, nucleic acids, toxins, and signaling molecules, that can traverse host barriers, modulate immune responses, and influence cancer progression. Their biogenesis varies by bacterial type, involving complex processes such as membrane blebbing, autolysin-mediated wall weakening, and explosive cell lysis. BEVs can suppress tumor growth, positioning them as promising candidates for innovative cancer therapies. Moreover, engineered BEVs have the potential to serve as sophisticated drug delivery vehicles for chemotherapeutic or photothermal agents, as well as novel vaccine platforms. Although tumor regression and enhanced T-cell responses mediated by BEVs have been demonstrated in numerous preclinical studies, their clinical translation remains challenging. In this review, we provide a comprehensive overview of BEVs derived from diverse bacterial strains, focusing on their roles in CRC pathogenesis and therapy, while highlighting key barriers to their clinical applications.
conclusionsWhile promising, challenges remain in standardizing isolation, ensuring safety, and optimizing tumor-targeting efficiency for clinical translation. Future research focusing on advanced engineering and rigorous validation is crucial to harness the full therapeutic potential of BEVs in CRC management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.